<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139428">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742182</url>
  </required_header>
  <id_info>
    <org_study_id>Circadian Rhythms in PD</org_study_id>
    <secondary_id>1K23NS072283-01A1</secondary_id>
    <nct_id>NCT01742182</nct_id>
  </id_info>
  <brief_title>Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease</brief_title>
  <official_title>Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board, Northwestern University</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disruption of sleep and alertness is one of the most disabling non-motor symptoms of
      Parkinson's disease (PD). Mechanisms leading to impaired sleep and alertness in PD are not
      well understood, and treatment options remain limited. The proposed research will examine
      markers of the circadian system, sleepiness and sleep quality in PD patients and healthy
      controls. Further, the project will examine effects of bright light exposure on circadin
      function, sleep and alertness in PD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>circadian rhythm of melatonin</measure>
    <time_frame>June 2012- May 2017</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>June 2012- May 2017</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Daytime Somnolence</measure>
    <time_frame>June 2012- May 2017</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD patients without sleep problems</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD patients with sleep problems</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>light exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD patients with sleep problem</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>light exposure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Light exposure</intervention_name>
    <arm_group_label>PD patients with sleep problems</arm_group_label>
    <arm_group_label>PD patients with sleep problem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank
             Criteria;

          2. PD Hoehn and Yahr stage 2-4;

          3. Pittsburgh Sleep Quality Index (PSQI) score &gt;5 in group 1, and ≤5 in group 2;

          4. Epworth Sleepiness Scale (ESS) score ≥10 in group 1, and &lt;10 in group 2;

        Control participants will be matched for gender and age with PD participants.

        Exclusion Criteria:

          1. Atypical or secondary forms of Parkinsonism;

          2. Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score
             of ≤ 26;

          3. Presence of depression defined as the Beck Depression Inventory (BDI) score &gt;14;

          4. Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to
             taper these drugs and will become eligible at least 4 weeks after the taper is
             completed;

          5. Use of SSRIs / SNRIs antidepressants, unless the participant has been on a stable
             dose for at least 3 months prior to the screening;

          6. Use of medications known to affect melatonin secretion;

          7. Unstable/serious medical illness.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandar Videnovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Wulf, MA</last_name>
    <phone>312-503-1999</phone>
    <email>l-wulf@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Williams, BA</last_name>
    <phone>312-503-5645</phone>
    <email>k-williams8@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleksandar Videnovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 5, 2012</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Aleksandar Videnovic</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Excessive Daytime Sleepiness</keyword>
  <keyword>Circadian Rhythms</keyword>
  <keyword>Light Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
